Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: A randomized, double-blind trial

Journal of Clinical Oncology

Volumn 18, Issue 21, 2000, Pages 3690-3698

  Feld, Ronald ^a   DePauw, Ben ^a   Berman, Steven ^a   Keating, Armand ^a   Ho, Winston ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; MEROPENEM;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SINGLE BLIND PROCEDURE; VOMITING;

EID: 0034331491     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.21.3690     Document Type: Article

References (30)

1. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer granulocytopenia
2. Ceftazidime combined with a short or a long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia
3. Overview of empiric antibiotic therapy for the febrile neutropenic patient
4. Beta-lactam antibiotic therapy in febrile granulocytopenic patients: A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone
5. A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies
6. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients
7. Early results of a comparative trial of ceftazidime versus cephalothin, carbenicillin and gentamicin in the treatment of febrile granulocytopenic patients
8. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia
9. Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: A meta-analysis
10. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever
11. A randomized prospective study of ceftazidime versus ceftazidime plus flucloxacillin in the empiric treatment of febrile episodes in severely neutropenic patients
12. Ceftazidime with and without vancomycin vs cephalothin, carbenicillin and gentamicin as the initial therapy of the febrile neutropenic pediatric cancer patient
13. Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: A randomized prospective study
14. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer
15. Monotherapy for fever and neutropenia in cancer patients: A randomized comparison of ceftazidime versus imipenem
16. A comparison of imipenem to aztreonam with vancomycin as initial therapy for febrile neutropenic cancer patients
17. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: A prospective, randomized multi-clinic study
18. Beta-lactam antibiotic therapy in febrile granulocytopenic patients: A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone
19. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients
20. Pharmacokinetics of meropenem compared to imipenem-cilastatin in young healthy males
21. Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients
22. Empiric monotherapy for febrile neutropenia: A randomized study comparing meropenem with ceftazidime
23. Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients
24. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer
25. Meropenem versus ceftazidime plus amikacin in the treatment of febrile episodes in neutropenic patients: A randomized study
26. The effect of different measures of outcome on the results of studies of empiric antibiotic therapy in febrile neutropenic patients
27. Methodology for clinical trials in cancer patients with febrile neutropenia: Do we have a consensus?
28. Empiric therapy for the febrile neutropenic patient: Design bias